摘要
钠-葡萄糖协同转运蛋白(SGLT2)抑制剂是一类作用于新靶点的降糖药物,目前已进入临床使用,美国FDA已经批准上市的有6种,中国CFDA也相继批准了达格列净(dapagliflozin)及恩格列净(empagliflozin)在我国上市。为了使临床医师及药师更好地了解和使用该类全新机制的糖尿病治疗药物,本文从该类药物的来源、化学结构、药理作用机制、药物代谢动力学特点、临床疗效与应用、不良反应及安全性进行了综述,以供参考。
The SGLT2 （sodium-dependent glucose transporters 2） inhibitor has been approved use clinically as a new target hypoglycemic drug. The FDA has been approved 6 these kind of drugs within 5 years. Meanwhile in China, dapagliflozin and empagliflozin has been approved use in clinical by CFDA. For better understanding and using this brand new mechanism antidiabetic drug, we clarified the source, chemical structure, pharmacological mechanism, pharmakinetic characteristic, clinical effect, clinical using, side effect and safety of this drug in this review. And wish it will be helpful for physicians and pharmacists.
作者
李鑫
李焕德
LI Xin1, LI Huan-de2.(1. Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha 410011; 2. Clinical Pharmacy Institute, Second Xiangya Hospital, Central South University, Changsha 41001)
出处
《中南药学》
CAS
2018年第3期289-296,共8页
Central South Pharmacy
关键词
2型糖尿病
SGLT2抑制剂
降糖药物
type 2 diabetes
sodium-dependent glucose transporters 2
hypoglycemic drug
